彝族儿童幽门螺杆菌感染HLA-DQA1免疫遗传学特征分析

目的研究人类白细胞抗原(HLA)DQA1基因位点上是否存在H.pylori感染的易感基因或抵抗基因，探讨免疫遗传因素在H.pylori感染中的作用。方法用聚合酶链反应-序列特异性引物(PCR-SSP)技术对用血清学试验及^13C尿素呼气实验确诊的31例H．pylori感染的彝族儿童及39例无感染儿童进行HLA．DQA1基因分型。结果感染组HLA-DQA1*0102等位基因频率明显高于对照组(14．52％vs3．85％，P=0．025，Pc=0．35)，OR=4．245(95％CI：1．097～16．428)；感染组HLA-DQA1*0302等位基因频率低于对照组(0 vs12．82％，P=0．003，Pc=0．042)，OR=1．147(95％CI：1．053-1．249)。结论在HLA-DQA1位点上，H．pflori感染的彝族儿童与对照组儿童存在免疫遗传学差异，HLA-DQA1*0102基因可能是彝族H．pylori感染的易感基因，而HLA-DQA1*0302基因则可能是抵抗基因和具有免疫抵抗作用。     

腹腔镜手术在老年女性妇科疾病中的应用价值

目的探讨腹腔镜手术在老年女性妇科手术中的安全性和应用价值。方法1998年5月-2003年5月，回顾性分析124例妇科疾病患者的临床资料(老年腹腔镜手术一组41例，非老年腹腔镜手术治疗组48例，老年经腹手术治疗组35例)。结果老年患者恶性肿瘤发病率明显高于非老年组(x^2=4．750，P=0．029)，经腹手术组的卵巢，输卵管恶性肿瘤患者多于腹腔镜手术组(x^2=14．302，P=0．01)，老年组待手术日明显长于非老年组(t=49．791，P=0．001)，附件手术腹腔镜组术中出血明显少于经腹手术组(t=11．430，P=0．006)，腹腔镜组肠功能恢复短于经腹手术组(t=8．79，P=0．001)。结论腹腔镜手术治疗老年妇科疾病的患者是安全、有效的。     

香菇多糖联合抗生素治疗恶性肿瘤围化疗期肺部感染120例临床观察

目的：本文观察香菇多糖对恶性肿瘤患者围化疗期肺部感染抗生素治疗的增效作用。方法：120例围化疗期发生肺部感染恶性肿瘤患者在接受抗生素治疗的同时，随机分成加用香菇多糖针和不加香菇多糖针静脉滴注两组。每组各60例。结果：接受抗生素及香菇多糖联合治疗的患者的有效率显著提高（P〈0．05）．临床症状、体征与X光胸部片改善时间大幅缩短。结论：香菇多糖对恶性肿瘤患者围化疗期肺部感染抗生素治疗有明显增效作用。     

尺桡骨中段旋转截骨术治疗先天性上尺桡关节融合及并发症探讨

目的探讨尺桡骨中段旋转截骨术治疗先天性上尺桡关节融合的优越性及并发症。方法对7例先天性上尺桡关节融合的患儿，行尺桡骨中段旋转截骨术，Ⅰ期旋转至所需位置。结果7例患儿随访2个月～3年，平均1年，7例中1例1侧术后发生缺血性肌挛缩，1例1侧发生钢板断裂，其余病例均于3个月内截骨处达骨性愈合，患肢功能满意。结论此术式是治疗先天性上尺桡关节融合的较理想的方法。     

更昔洛韦治疗特发性血小板减少性紫癜应用指征

目的探讨更昔洛韦(GCV)治疗人巨细胞病毒(HCMV)感染相关的特发性血小板减少性紫癜的(ITP)应用指征。方法选择血清HCMV DNA PCR和(或)HCMV IgM检测呈阳性ITP患儿46例,采用逆转聚合酶扩增反应(RT-PCR)检测巨核系祖细胞中HCMV晚期抗原mRNA,并行GCV治疗,判定其疗效及应用指征。结果46例血清HCMV-DNA PCR阳性和(或)血清HCMV-IgM阳性的ITP骨髓巨核祖细胞HCMV晚期抗原基因mRNA阳性19例,GCV治疗有效16例,mRNA阴性27例,GCV治疗有效4例。阳性组疗效高于阴性组,有显著性差异(P<0.01)。结论HCMV感染的ITP患儿,若对常规治疗无效,应检测其巨核祖细胞内HCMV晚期抗原基因mRNA,阳性者是应用更昔洛韦的有效指征。     

Effect of a structured asthma education program on hospitalized asthmatic children: A randomized controlled study

BACKGROUND: The aim of this study was to compare the effectiveness of an intensive asthma education program (group B) with that of a standard asthma education program (group A). METHODS: A prospective randomized single blinded study was conducted in the pediatric department of a public hospital in Hong Kong. Children aged 2-15 years admitted to the pediatric department with an acute attack of asthma were recruited. A standard asthma education program (group A) or an intensive asthma education program (group B) for children were offered. The main outcome measures include the number of visits to the emergency department and the number of hospitalization for asthma during the 3 month follow-up period. RESULTS: A total of 45 children were in group A and 55 in group B. Group B had statistically significant reductions in the number of visits to the emergency department and the number of hospitalizations. Drug compliance was also significantly improved in group B. Parents' satisfaction rate was also higher in group B. CONCLUSION: The intensive asthma education program might be more cost effective than the standard asthma education program in the management of asthmatic children admitted to hospital in Hong Kong.     

凤尾草鉴别研究

目的：研究凤尾草（凤尾蕨）药材的鉴别方法和质量标准。方法：对药材凤尾草药材性状、显微特征进行研究。结果与结论：为药材凤尾草的质量标准的制订提高和开发利用提供科学依据。     

波依定与洛汀新治疗不同中医证型高血压疗效比较

目的:观察波依定与洛汀新对不同中医证型高血压的疗效是否具有中草药的某些特征,能否按中医辨证选择抗高血压药.方法:按照WHO的标准明确高血压诊断与分级,根据<中药新药临床研究指导原则>分为4型.216例患者随机分为两组,分别给予波依定与洛汀新治疗,疗程4周.分析对总体血压和不同证型血压的影响,以及对不同症状的疗效有无差异.结果:两种药物降低患者总体血压的幅度基本相同;但分层研究,对4种中医证型患者的血压的降低程度明显不同,洛汀新对肝火亢盛型血压降低幅度更明显,波依定对痰湿壅盛型比其它三型降压更好;对阴虚阳亢型和阴阳两虚型两组之间差异无显著性.对各种证型症状的改善作用也显示同样的结果.结论:抗高血压药对不同中医证型高血压的疗效不同,表明西药也同样具有中草药的某些特性,可以根据中医辨证选择抗高血压药.     

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.     

Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.

PURPOSE AND EXPERIMENTAL DESIGN: The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in nonsmoking lung cancer. Therefore, we investigated protein expression and promoter hypermethylation of hMLH1 and hMSH2 genes in the tumor specimens from 105 nonsmoking female non-small cell lung cancer (NSCLC) patients. Immunohistochemistry and restriction enzyme-based multiplex PCR were used to examine the protein expression and promoter hypermethylation, respectively. The occurrence of gene/protein alteration for each gene was compared with the patients' clinicopathologic variables as well as the overall survival and cancer-specific survival rates. RESULTS: Protein expression alteration and promoter hypermethylation were observed in 66% to 67% and 30% to 34% of tumor specimens for hMLH1 and hMSH2 genes, respectively. Loss of hMLH1 and hMSH2 protein expression was significantly associated with their promoter hypermethylation (P < 0.0001 and P = 0.049). The overall survival and cancer-specific survival rates were significantly lower in patients with promoter hypermethylation of hMSH2 gene than in those without hypermethylation (P = 0.038 and P = 0.004). The poor prognosis was still especially significant in adenocarcinoma (P = 0.035 and P = 0.061) and early-stage NSCLC patients (P = 0.067 and P = 0.041). CONCLUSION: Our data suggest that hMLH1 is the major altered mismatch repair gene involved in nonsmoking NSCLC tumorigenesis and that promoter methylation is the predominant mechanism in hMLH1 and hMSH2 deregulation. In addition, promoter methylation of the hMSH2 gene may be a potential prognostic factor in nonsmoking female lung cancer.